Get the Stockscreener App
2.72
0.74%
0.02
After Hours:
2.68
-0.04
-1.47%
Annovis Bio Inc stock is traded at $2.72, with a volume of 145.53K.
It is up +0.74% in the last 24 hours and down -4.90% over the past month.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
See More
Previous Close:
$2.70
Open:
$2.75
24h Volume:
145.53K
Relative Volume:
0.34
Market Cap:
$53.00M
Revenue:
-
Net Income/Loss:
$-40.94M
P/E Ratio:
-0.7083
EPS:
-3.84
Net Cash Flow:
$-22.97M
1W Performance:
+4.62%
1M Performance:
-4.90%
6M Performance:
-0.37%
1Y Performance:
-64.95%
1-Day Range:
$2.60
$2.8399
1-Week Range:
$2.53
$2.95
52-Week Range:
$1.11
$10.54
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.72 | 52.61M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis Bio’s Promising Alzheimer’s Drug Trial: What Investors Need to Know - TipRanks
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results - GlobeNewswire
ANNOVIS BIO -REDH Earnings Results: $ANVS Reports Quarterly Earnings - Quiver Quantitative
Annovis Reports Q2 2025 Financial Results, Drives Enrollment for Phase 3 AD Trial - AInvest
Annovis Bio, Inc. SEC 10-Q Report - TradingView
Annovis Advances Alzheimer's Phase 3 Trial With 76 Sites, Reports Stronger Cash Position - Stock Titan
Annovis Bio Secures Full Patent Protection for New Crystal Form of Alzheimer’s Drug Buntanetap - MSN
Annovis Bio ANVS Q2 2025 Earnings Preview Upside Potential on Strategic Innovations - AInvest
How sensitive is Annovis Bio Inc. to inflationTechnical Confluence Stock Ideas - mustnews.co.kr
RSI Reset May Fuel Rebound in Annovis Bio Inc.Weekly Stock Watch With Growth Focus Expanded - beatles.ru
Annovis Bio completes full patent transfer to crystal buntanetap - TipRanks
Annovis Completes Full Patent Transfer to Crystal Buntanetap - Santé log
Annovis secures IP protection for both forms of buntanetap By Investing.com - Investing.com Australia
Annovis secures IP protection for both forms of buntanetap - Investing.com India
Annovis Locks Down Patent Protection Until 2046 for Promising Alzheimer's and Parkinson's Treatment - Stock Titan
Bullish Candlestick Pattern Forms in Annovis Bio Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
How many analysts rate Annovis Bio Inc. as a “Buy”Achieve rapid financial growth with expert picks - Jammu Links News
What makes Annovis Bio Inc. stock price move sharplyBuild a strong portfolio for long-term success - Jammu Links News
What are analysts’ price targets for Annovis Bio Inc. in the next 12 monthsAccelerated earnings growth - Jammu Links News
What are Annovis Bio Inc. company’s key revenue driversFree Trend-Following Techniques - Jammu Links News
How does Annovis Bio Inc. compare to its industry peersMassive portfolio appreciation - Jammu Links News
Is Annovis Bio Inc. stock overvalued or undervaluedRapid growth trajectories - Jammu Links News
How volatile is Annovis Bio Inc. stock compared to the marketGrow your wealth steadily and securely - Jammu Links News
Why is Annovis Bio Inc. stock attracting strong analyst attentionUnlock powerful portfolio optimization tools - Jammu Links News
Recovery Setup Building in Annovis Bio Inc. Experts SayStrong Buy With Technical Confidence Supported - metal.it
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - 富途牛牛
What catalysts could drive Annovis Bio Inc. stock higher in 2025Swing Trade Insights With Proven Results - Jammu Links News
Will Annovis Bio Inc. Stock Benefit from AI and Green Energy TrendsTrade Scanner With Buy Zone Alerts Flagged - metal.it
Annovis Bio Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingTrade Insight With Community Collaboration Supported - metal.it
Will Annovis Bio Inc. stock split in the near futureChart-Based Trade Entries Gain Analyst Support - metal.it
What is Annovis Bio Inc. company’s growth strategyMaximize your returns with expert insights - Jammu Links News
Should I hold or sell Annovis Bio Inc. stock in 2025Accelerated capital growth - Jammu Links News
Is Annovis Bio Inc. a growth stock or a value stockConsistently exceptional gains - Jammu Links News
Why Annovis Bio Inc. stock attracts strong analyst attentionBreakout Momentum Stocks - metal.it
Annovis Bio Inc. Stock Analysis and ForecastFree Predictions - PrintWeekIndia
Is Annovis Bio Inc. a good long term investmentFree Real-Time Stock Data - PrintWeekIndia
What analysts say about Annovis Bio Inc. stockExceptional growth trajectory - PrintWeekIndia
Annovis Bio Inc.’s Promising Alzheimer’s Drug Trial: Key Updates for Investors - TipRanks
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):